Caliber Wealth Management LLC KS Has $321,000 Stock Holdings in Jazz Pharmaceuticals PLC $JAZZ

Caliber Wealth Management LLC KS increased its holdings in shares of Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) by 32.7% during the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 3,024 shares of the specialty pharmaceutical company’s stock after buying an additional 745 shares during the period. Caliber Wealth Management LLC KS’s holdings in Jazz Pharmaceuticals were worth $321,000 at the end of the most recent quarter.

Other hedge funds have also added to or reduced their stakes in the company. Philip James Wealth Mangement LLC boosted its position in Jazz Pharmaceuticals by 42.0% during the 2nd quarter. Philip James Wealth Mangement LLC now owns 15,797 shares of the specialty pharmaceutical company’s stock worth $1,676,000 after buying an additional 4,675 shares during the period. State of Alaska Department of Revenue increased its stake in shares of Jazz Pharmaceuticals by 75.1% in the 2nd quarter. State of Alaska Department of Revenue now owns 57,933 shares of the specialty pharmaceutical company’s stock valued at $6,147,000 after acquiring an additional 24,850 shares in the last quarter. Envestnet Portfolio Solutions Inc. increased its stake in Jazz Pharmaceuticals by 38.9% during the 1st quarter. Envestnet Portfolio Solutions Inc. now owns 4,369 shares of the specialty pharmaceutical company’s stock valued at $542,000 after purchasing an additional 1,223 shares in the last quarter. Inspire Investing LLC purchased a new position in Jazz Pharmaceuticals during the 1st quarter worth $689,000. Finally, Baird Financial Group Inc. purchased a new position in Jazz Pharmaceuticals during the 1st quarter worth $539,000. 89.14% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling at Jazz Pharmaceuticals

In related news, Director Bruce C. Cozadd sold 6,000 shares of the company’s stock in a transaction that occurred on Tuesday, September 2nd. The shares were sold at an average price of $128.62, for a total value of $771,720.00. Following the transaction, the director directly owned 429,973 shares in the company, valued at approximately $55,303,127.26. This represents a 1.38% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders have sold 11,500 shares of company stock valued at $1,525,280 in the last quarter. 4.30% of the stock is currently owned by corporate insiders.

Jazz Pharmaceuticals Stock Up 0.7%

JAZZ stock opened at $138.52 on Thursday. The company has a current ratio of 1.62, a quick ratio of 1.37 and a debt-to-equity ratio of 1.17. The company’s 50 day moving average is $129.60 and its 200 day moving average is $116.44. The stock has a market cap of $8.40 billion, a price-to-earnings ratio of -20.58, a price-to-earnings-growth ratio of 8.44 and a beta of 0.28. Jazz Pharmaceuticals PLC has a 1-year low of $95.49 and a 1-year high of $148.06.

Jazz Pharmaceuticals (NASDAQ:JAZZ) last posted its quarterly earnings data on Tuesday, August 5th. The specialty pharmaceutical company reported ($8.25) earnings per share for the quarter, missing the consensus estimate of ($5.61) by ($2.64). The company had revenue of $1.05 billion during the quarter, compared to the consensus estimate of $1.05 billion. Jazz Pharmaceuticals had a positive return on equity of 5.02% and a negative net margin of 9.91%.The firm’s revenue for the quarter was up 2.1% on a year-over-year basis. During the same quarter last year, the company posted $5.30 earnings per share. Jazz Pharmaceuticals has set its FY 2025 guidance at 4.800-5.600 EPS. Sell-side analysts predict that Jazz Pharmaceuticals PLC will post 16.96 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

JAZZ has been the topic of a number of analyst reports. Truist Financial lifted their price objective on shares of Jazz Pharmaceuticals from $200.00 to $205.00 and gave the stock a “buy” rating in a report on Thursday, August 28th. Needham & Company LLC reaffirmed a “buy” rating and set a $202.00 price objective on shares of Jazz Pharmaceuticals in a report on Thursday, August 28th. Deutsche Bank Aktiengesellschaft began coverage on shares of Jazz Pharmaceuticals in a report on Tuesday, July 15th. They set a “buy” rating and a $152.00 price objective on the stock. Morgan Stanley upped their price objective on shares of Jazz Pharmaceuticals from $167.00 to $180.00 and gave the company an “overweight” rating in a report on Monday. Finally, Royal Bank Of Canada upped their price target on Jazz Pharmaceuticals from $145.00 to $151.00 and gave the company an “outperform” rating in a research report on Thursday, August 28th. Fourteen investment analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $179.80.

Jazz Pharmaceuticals Profile

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.